{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:19:34Z","timestamp":1790795974099,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent studies have found that inflammatory response is involved in the pathogenesis of ovarian cancer. Advanced ovarian cancer is often presented with ascites that is rich in cytokines, inflammatory factors or cancer cells. Therefore, it is important to study the microenvironment of ascites in order to further clarify the occurrence and progression of ovarian cancer. As a pro-inflammatory factor, the Cyr61 expression patterns are inconsistent in human tumors. Although it has been reported that Cyr61 is related to the progression of ovarian cancer, its specific mechanism is not yet clear. This study sought to evaluate the Cyr61 levels of ascites, serum and different tissues of ovarian cancer to explore the potential association of Cyr61with the tumor-associated inflammatory microenvironment of EOC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Tumor specimens were procured from patients with ovarian serous cystadenocarcinoma and ovarian serous cystadenoma. Cyr61 and IL-6 levels of serum or ascites were determined by ELISA (Enzyme-Linked ImmunoSorbent Assay), while Cyr61 expressions of different ovarian tumor tissues were evaluated by IHC (Immunohistochemistry). Then the correlation of Cyr61 level in ascites with clinicopathologic features was analyzed. And other laboratory data were obtained from medical records.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both in ascites and serum, significantly higher Cyr61 levels were found in ovarian serous cystadenocarcinoma. In malignant ascites, higher Cyr61 level of ovarian serous cystadenocarcinoma was more closely associated with FIGO stage, initial tumor size &gt;\u200910\u2009cm and the residual tumor size. And the increased IL-6 level was linearly related to Cyr61 level. Moreover, the serum levels of Cyr61, IL-6 and CRP in advanced stage of ovarian cancer were much higher than those in early stage. Lastly, the IHC data demonstrate that Cyr61 expression of ovarian serous adenocarcinoma was higher than that of ovarian serous cystadenoma, but it was lower than the paired metastatic lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>As a pro-inflammatory factor, increased ascites Cyr61 level is associated with FIGO stage, initial tumor size &gt;\u200910\u2009cm and the residual tumor size. Moreover, serum Cyr61 may be used as a potential marker for EOC inflammatory response. Finally, Cyr61 may be involved in the process of tumor metastasis and progression by producing IL-6 and CRP in the EOC inflammatory microenvironment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6321-x","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T17:02:50Z","timestamp":1574701370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress"],"prefix":"10.1186","volume":"19","author":[{"given":"Jun","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfen","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huidan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baihua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruojin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"1","key":"6321_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"6917","key":"6321_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860\u20137.","journal-title":"Nature."},{"issue":"2","key":"6321_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1158\/0008-5472.CAN-06-2941","volume":"67","author":"H Kulbe","year":"2007","unstructured":"Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor- \u03b1 generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007;67(2):585\u201392.","journal-title":"Cancer Res"},{"issue":"4","key":"6321_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"Johanna A. Joyce","year":"2008","unstructured":"Joyce J. A, Pollard J.W. \u201cMicroenvironmental regulation of metastasis\u201d. Nat Rev Cancer 2009; 9(4): 239\u2013252.","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"6321_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/0008-5472.CAN-11-2178","volume":"72","author":"H Kulbe","year":"2012","unstructured":"Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012;72(1):66\u201375.","journal-title":"Cancer Res"},{"key":"6321_CR6","doi-asserted-by":"crossref","unstructured":"Hussian S. P, Harris C.C. \u201cInflammation and cancer: an ancient link with novel potentials\u201d. Int J Cancer 2007; 121(11): 2373\u20132380.","DOI":"10.1002\/ijc.23173"},{"issue":"5","key":"6321_CR7","first-page":"1066","volume":"48","author":"GB Mills","year":"1988","unstructured":"Mills GB, May C, McGill M, Roifman CM, Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988;48(5):1066\u201371.","journal-title":"Cancer Res"},{"issue":"1","key":"6321_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1479-5876-2-23","volume":"2","author":"RS Freedman","year":"2004","unstructured":"Freedman RS, Deavers M, Liu J, Wang E. Peritoneal inflammation \u2013 a microenvironment for epithelial ovarian cancer (EOC). J Transl Med. 2004;2(1):23.","journal-title":"J Transl Med"},{"issue":"3","key":"6321_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1665-2681(19)30865-8","volume":"13","author":"L Fang","year":"2014","unstructured":"Fang L, Xinjuan K, Qian D, Jin Y, Yuhu S. Evaluation of tumor markers for the differerntial diagnosis of benign and malignant ascites. Ann Hepatol. 2014;13(3):357\u201363.","journal-title":"Ann Hepatol"},{"issue":"5","key":"6321_CR10","first-page":"566","volume":"2","author":"I Matte","year":"2012","unstructured":"Matte I, Lane D, Laplante C, Rancourt C, Piche A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res. 2012;2(5):566\u201380.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"6321_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/1471-2407-11-210","volume":"11","author":"D Lane","year":"2011","unstructured":"Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11(1):210.","journal-title":"BMC Cancer"},{"issue":"1","key":"6321_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12885-015-1511-7","volume":"15","author":"D Lane","year":"2015","unstructured":"Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, et al. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015;15(1):492.","journal-title":"BMC Cancer"},{"issue":"2","key":"6321_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jcb.20810","volume":"98","author":"EC Heng","year":"2006","unstructured":"Heng EC, Huang Y, Black SA Jr, Trackman PC. CCN2, connective tissue growth factor, stimulates collagen deposition by gingival fibroblasts via module 3 and alpha6- and beta1 integrins. J Cell Biochem. 2006;98(2):409\u201320.","journal-title":"J Cell Biochem"},{"issue":"32","key":"6321_CR14","doi-asserted-by":"publisher","first-page":"24953","DOI":"10.1074\/jbc.M003040200","volume":"275","author":"N Chen","year":"2000","unstructured":"Chen N, Chen CC, Lau LF. Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin alpha 6 beta 1 and cell surface heparin sulfate proteoglycans. J Biol Chem. 2000;275(32):24953\u201361.","journal-title":"J Biol Chem"},{"issue":"4","key":"6321_CR15","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1210\/endo.143.4.8731","volume":"143","author":"TM Grzeszkiewicz","year":"2002","unstructured":"Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha (6) beta (1) and cell surface heparin sulfate proteoglycans. Endocrinology. 2002;143(4):1441\u201350.","journal-title":"Endocrinology."},{"issue":"12","key":"6321_CR16","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1182\/blood.V99.12.4457","volume":"99","author":"JM Schober","year":"2002","unstructured":"Schober JM, Chen N, Grzeszkiewicz TM, Jovanovic I, Emeson EE, Ugarova TP, Ye RD, Lau LF, Lam SC. Identification of integrin alpha (M) beta (2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood. 2002;99(12):4457\u201365.","journal-title":"Blood."},{"issue":"53","key":"6321_CR17","doi-asserted-by":"publisher","first-page":"8178","DOI":"10.1038\/sj.onc.1205682","volume":"21","author":"MS Tsai","year":"2002","unstructured":"Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene. 2002;21(53):8178\u201385.","journal-title":"Oncogene."},{"issue":"6","key":"6321_CR18","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1158\/0008-5472.CAN-03-0666","volume":"64","author":"D Xie","year":"2004","unstructured":"Xie D, Yin D, Tong X, O\u2019Kelly J, Mori A, Miller C, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and \u03b2-catenon-TCF\/Lef signaling pathways. Cancer Res. 2004;64(6):1987\u201396.","journal-title":"Cancer Res"},{"issue":"6","key":"6321_CR19","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1152\/japplphysiol.01093.2004","volume":"98","author":"D Zhou","year":"2005","unstructured":"Zhou D, Herrick DJ, Rosenbloom J, Chaqour B. Cyr61 mediates the expression of VEGF, \u03b1v-integrin, and \u03b1-actin genes through cytoskeletally based mechanotransduction mechanisms in bladder smooth muscle cell. J Appl Physiol. 2005;98(6):2344\u201354.","journal-title":"J Appl Physiol"},{"issue":"19","key":"6321_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000834","volume":"94","author":"J Lin","year":"2015","unstructured":"Lin J, Li N, Chen H, Liu C, Yang B, Ou Q. Serum CYR61 is associated with clinical disease activity and inflammation in patients with systemic lupus erythematosus. Medicine (Baltimore). 2015;94(19):e834.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"6321_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/mi.2015.19","volume":"8","author":"JS Choi","year":"2015","unstructured":"Choi JS, Kim KH, Lau LF. The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol. 2015;8(6):1285\u201396.","journal-title":"Mucosal Immunol"},{"issue":"11","key":"6321_CR22","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.4049\/jimmunol.1103201","volume":"188","author":"J Lin","year":"2012","unstructured":"Lin J, Zhou Z, Huo R, Xiao L, Ooyang G, Wang L, Sun Y, Shen B, Li D, Li N. Cyr61 induces IL-6 production by fibroblast-like synoviocytes promoting Th17 differentiation in rtheumatoid arthritis. J Immunol. 2012;188(11):5776\u201384.","journal-title":"J Immunol"},{"key":"6321_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clim.2016.11.003","volume":"174","author":"P Wu","year":"2017","unstructured":"Wu P, Ma G, Zhu X, Gu T, Zhang J, Sun Y, Xu H, Huo R, Wang B, et al. Cyr61\/CCN1 is involved in the pathogenesis of psoriasis vulgaris via promoting IL-8 production by keratinocytes in a JNK\/NF-kB pathway. Clin Immunol. 2017;174:53\u201362.","journal-title":"Clin Immunol"},{"issue":"6","key":"6321_CR24","doi-asserted-by":"publisher","first-page":"R187","DOI":"10.1186\/ar4377","volume":"15","author":"X Zhu","year":"2013","unstructured":"Zhu X, Xiao L, Huo R, Zhang J, Lin J, Xie J, Sun S, He Y, Sun Y, Zhou Z, Shen B, Li N. Cyr61 is involved in neutrophil infiltration in joints by inducing IL-8 production by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):R187.","journal-title":"Arthritis Res Ther"},{"issue":"28","key":"6321_CR25","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1038\/onc.2011.496","volume":"31","author":"LG Harris","year":"2012","unstructured":"Harris LG, Pannell LK, Singh S, Samant RS, Shevde LA. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of Cyr61. Oncogene. 2012;31(28):3370\u201380.","journal-title":"Oncogene."},{"issue":"4","key":"6321_CR26","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.juro.2009.12.006","volume":"183","author":"KB D\u2019Antonio","year":"2010","unstructured":"D\u2019Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH. Extracellular matrix associated protein CYR61 is linked to prostate cancer development. J Urol. 2010;183(4):1604\u201310.","journal-title":"J Urol"},{"key":"6321_CR27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/1476-4598-13-236","volume":"13","author":"CH Hou","year":"2014","unstructured":"Hou CH, Lin FL, Hou SM, Liu JF. Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1\/MEK\/ERK\/Elk-1\/TWIST-1 signaling pathway. Mol Cancer. 2014;13:236.","journal-title":"Mol Cancer"},{"issue":"2","key":"6321_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/0008-5472.CAN-10-1496","volume":"71","author":"CW Lo","year":"2011","unstructured":"Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011;71(2):424\u201334.","journal-title":"Cancer Res"},{"issue":"2","key":"6321_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ygyno.2015.05.009","volume":"138","author":"K Nonna","year":"2015","unstructured":"Nonna K, Kevin HE, Anm Nazmul HK, Kassondra SG, Kelly LS, et al. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-\u03b1 and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015;138(2):352\u20137.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"6321_CR30","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1038\/jid.2015.231","volume":"135","author":"Y Sun","year":"2015","unstructured":"Sun Y, Zhang J, Zhou Z, Wu P, Huo R, Wang B, Shen Z, Li H, Zhai T, Shen B, Chen X, Li N. CCN1, a pro-inflammatory factor, aggravates psoriasis skin lesions bu promoting keratinocyte activation. J Invest Dermatol. 2015;135(11):2666\u201375.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"6321_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-011-1135-y","volume":"61","author":"J Lin","year":"2012","unstructured":"Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen B, Wang R, Li N. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother. 2012;61(5):677\u201387.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"6321_CR32","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","volume":"30","author":"L Yang","year":"2016","unstructured":"Yang L, Cao X. Characteristics and significance of pre-metastatic niche. Cancer Cell. 2016;30(5):668\u201381.","journal-title":"Cancer Cell"},{"key":"6321_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cytogfr.2018.01.007","volume":"39","author":"VS Farajzadeh","year":"2018","unstructured":"Farajzadeh VS, Keshavarz-Fathi M, Silvestris N, Argentiero A, Rezaei N. The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine Growth Factor Rev. 2018;39:46\u201361.","journal-title":"Cytokine Growth Factor Rev"},{"key":"6321_CR34","doi-asserted-by":"crossref","unstructured":"Liao Z, Tan ZW, Zhu P, Tan NS. Cancer-associated fibroblasts in tumor microenvironment-Accomplices in tumor malignancy. Cell Immunol. 2018; Jan 31.","DOI":"10.1016\/j.cellimm.2017.12.003"},{"key":"6321_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.semcancer.2017.08.001","volume":"47","author":"L Yang","year":"2017","unstructured":"Yang L, Lin PC. Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Semin Cancer Biol. 2017;47:185\u201395.","journal-title":"Semin Cancer Biol"},{"issue":"32","key":"6321_CR36","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.2174\/1381612823666170613080919","volume":"23","author":"E Voronov","year":"2017","unstructured":"Voronov E, Apte RN. Targeting the tumor microenvironment by intervention in interleukin-1 biology. Curr Pharm Des. 2017;23(32):4893\u2013905.","journal-title":"Curr Pharm Des"},{"issue":"29","key":"6321_CR37","doi-asserted-by":"publisher","first-page":"47518","DOI":"10.18632\/oncotarget.17671","volume":"8","author":"S Blank","year":"2017","unstructured":"Blank S, Nienh\u00fcser H, Dreikhausen L, Sisic L, Heger U, Ott K, Schmidt T. Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer. Oncotarget. 2017;8(29):47518\u201332.","journal-title":"Oncotarget."},{"key":"6321_CR38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.","journal-title":"Front Oncol"},{"issue":"1","key":"6321_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ijc.28335","volume":"134","author":"S Reinart","year":"2014","unstructured":"Reinart S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134(1):32\u201342.","journal-title":"Int J Cancer"},{"issue":"8","key":"6321_CR40","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","volume":"73","author":"EM Dijkgraaf","year":"2013","unstructured":"Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, Jha V, et al. Chemotherapy alters monocyte differentiation to favour generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013;73(8):2480\u201392.","journal-title":"Cancer Res"},{"issue":"5","key":"6321_CR41","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ijc.29386","volume":"137","author":"J Kotsopoulos","year":"2015","unstructured":"Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, et al. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2015;137(5):1136\u201346.","journal-title":"Int J Cancer"},{"key":"6321_CR42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/bs.vh.2018.01.019","volume":"107","author":"JS Richards","year":"2018","unstructured":"Richards JS. From follicular development and ovulation to ovarian cancers: an unexpected journey. Vitam Horm. 2018;107:453\u201372.","journal-title":"Vitam Horm"},{"issue":"2","key":"6321_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neo.2015.12.003","volume":"18","author":"S Sapoznik","year":"2016","unstructured":"Sapoznik S, Bahar-Shany K, Brand H, Pinto Y, Gabay O, Glick-Saar E, Dor C, et al. Activation-induced cytidine deaminase links ovulation-induced inflammation and serous carcinogenesis. Neoplasia. 2016;18(2):90\u20139.","journal-title":"Neoplasia."},{"issue":"9","key":"6321_CR44","doi-asserted-by":"publisher","first-page":"R411","DOI":"10.1530\/ERC-16-0209","volume":"23","author":"C Cardenas","year":"2016","unstructured":"Cardenas C, Alvero AB, Yun BS, Mor G. Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocr Relat Cancer. 2016;23(9):R411\u201322.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"6321_CR45","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1038\/s41598-018-23062-6","volume":"8","author":"PC Benias","year":"2018","unstructured":"Benias PC, Wells RG, Sackey-Aboagye B, Klavan H, Reidy J, Buonocore D, Miranda M, Kornacki S, Wayne M, Carr-Locke DL, Theise ND. Structure and distribution of an unrecognized interstitium in human tissues. Sci Rep. 2018;8(1):4947.","journal-title":"Sci Rep"},{"key":"6321_CR46","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3892\/ijo.2015.3122","volume":"47","author":"KA So","year":"2015","unstructured":"So KA, Min KJ, Hong JH, Lee JK. Interleukin-6 expression by interactions between gynecologic cancer vells and human mesenchymal stem cells promotes epithelial-mesenchymal transition. Int J Oncol. 2015;47:1451\u20139.","journal-title":"Int J Oncol"},{"issue":"11","key":"6321_CR47","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/sj.bjc.6600956","volume":"88","author":"T Bachelot","year":"2003","unstructured":"Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 2003;88(11):1721\u20136.","journal-title":"Br J Cancer"},{"issue":"3","key":"6321_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1006\/gyno.1998.4974","volume":"69","author":"A Maccio","year":"1998","unstructured":"Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69(3):248\u201352.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"6321_CR49","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1158\/0008-5472.CAN-10-2583","volume":"71","author":"AD Gregory","year":"2011","unstructured":"Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71(7):2411\u20136.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6321-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6321-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:19:53Z","timestamp":1606177193000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6321-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6321"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6321-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"18 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of the Renji Hospital approved all the tumor specimens used for this study. All the participating patients in this study have signed the informed consent forms.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1140"}}